Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles.
ComplicationsHyperlipoprotéinémieGestion
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent l'obésité, le tabagisme, et une alimentation riche en graisses saturées.
Facteurs de risqueObésitéAlimentation
#2
L'âge influence-t-il le risque ?
Oui, le risque augmente avec l'âge, surtout après 45 ans chez les hommes et 55 ans chez les femmes.
ÂgeFacteurs de risqueHyperlipoprotéinémie
#3
Le stress a-t-il un impact sur cette condition ?
Oui, le stress chronique peut contribuer à des comportements malsains et à l'hyperlipoprotéinémie.
StressHyperlipoprotéinémieComportements malsains
#4
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux d'hyperlipoprotéinémie augmentent le risque.
Antécédents familiauxHyperlipoprotéinémieFacteurs de risque
#5
Le diabète est-il un facteur de risque ?
Oui, le diabète de type 2 est un facteur de risque majeur pour l'hyperlipoprotéinémie.
DiabèteHyperlipoprotéinémieFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperlipoprotéinémie de type II : Questions médicales les plus fréquentes",
"headline": "Hyperlipoprotéinémie de type II : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperlipoprotéinémie de type II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-28",
"dateModified": "2025-03-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperlipoprotéinémie de type II"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Erreurs innées du métabolisme lipidique",
"url": "https://questionsmedicales.fr/mesh/D008052",
"about": {
"@type": "MedicalCondition",
"name": "Erreurs innées du métabolisme lipidique",
"code": {
"@type": "MedicalCode",
"code": "D008052",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C18.452.648.398"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hypercholestérolémie familiale homozygote",
"alternateName": "Homozygous Familial Hypercholesterolemia",
"url": "https://questionsmedicales.fr/mesh/D000090542",
"about": {
"@type": "MedicalCondition",
"name": "Hypercholestérolémie familiale homozygote",
"code": {
"@type": "MedicalCode",
"code": "D000090542",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C18.452.648.398.481.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hyperlipoprotéinémie de type II",
"alternateName": "Hyperlipoproteinemia Type II",
"code": {
"@type": "MedicalCode",
"code": "D006938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Olga I Afanasieva",
"url": "https://questionsmedicales.fr/author/Olga%20I%20Afanasieva",
"affiliation": {
"@type": "Organization",
"name": "Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia."
}
},
{
"@type": "Person",
"name": "Marat V Ezhov",
"url": "https://questionsmedicales.fr/author/Marat%20V%20Ezhov",
"affiliation": {
"@type": "Organization",
"name": "A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia."
}
},
{
"@type": "Person",
"name": "Vincent A Pallazola",
"url": "https://questionsmedicales.fr/author/Vincent%20A%20Pallazola",
"affiliation": {
"@type": "Organization",
"name": "Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Vasanth Sathiyakumar",
"url": "https://questionsmedicales.fr/author/Vasanth%20Sathiyakumar",
"affiliation": {
"@type": "Organization",
"name": "Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Jihwan Park",
"url": "https://questionsmedicales.fr/author/Jihwan%20Park",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37019248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/36795508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FJC.0000000000001404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.",
"datePublished": "2024-07-07",
"url": "https://questionsmedicales.fr/article/38972879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-65609-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35508401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/heartjnl-2021-320556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.",
"datePublished": "2023-02-16",
"url": "https://questionsmedicales.fr/article/36727585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15723"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies métaboliques et nutritionnelles",
"item": "https://questionsmedicales.fr/mesh/D009750"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies métaboliques",
"item": "https://questionsmedicales.fr/mesh/D008659"
},
{
"@type": "ListItem",
"position": 4,
"name": "Erreurs innées du métabolisme",
"item": "https://questionsmedicales.fr/mesh/D008661"
},
{
"@type": "ListItem",
"position": 5,
"name": "Erreurs innées du métabolisme lipidique",
"item": "https://questionsmedicales.fr/mesh/D008052"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hyperlipoprotéinémie de type II",
"item": "https://questionsmedicales.fr/mesh/D006938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperlipoprotéinémie de type II - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperlipoprotéinémie de type II",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperlipoprotéinémie de type II",
"description": "Comment diagnostiquer l'hyperlipoprotéinémie de type II ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels niveaux de LDL indiquent ce type d'hyperlipoprotéinémie ?\nL'hyperlipoprotéinémie de type II est-elle héréditaire ?\nQuels symptômes peuvent indiquer un diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Proprotein+Convertase+9#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperlipoprotéinémie de type II",
"description": "Quels sont les symptômes courants de cette condition ?\nPeut-on observer des dépôts cutanés ?\nL'hyperlipoprotéinémie de type II cause-t-elle des douleurs ?\nQuels signes cliniques peuvent apparaître ?\nY a-t-il des symptômes liés aux maladies cardiovasculaires ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Proprotein+Convertase+9#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperlipoprotéinémie de type II",
"description": "Comment prévenir l'hyperlipoprotéinémie de type II ?\nLe contrôle du poids est-il important ?\nLe tabagisme influence-t-il cette condition ?\nLes examens réguliers sont-ils nécessaires ?\nL'éducation sur la santé est-elle utile ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Proprotein+Convertase+9#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperlipoprotéinémie de type II",
"description": "Quels traitements sont disponibles pour cette condition ?\nLes changements de mode de vie sont-ils recommandés ?\nDes médicaments autres que les statines sont-ils utilisés ?\nQuelle est l'importance du suivi médical ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Proprotein+Convertase+9#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperlipoprotéinémie de type II",
"description": "Quelles complications peuvent survenir ?\nL'hyperlipoprotéinémie de type II peut-elle causer des AVC ?\nY a-t-il un risque de crise cardiaque ?\nComment l'hyperlipoprotéinémie affecte-t-elle les reins ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Proprotein+Convertase+9#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperlipoprotéinémie de type II",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLe stress a-t-il un impact sur cette condition ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe diabète est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Proprotein+Convertase+9#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperlipoprotéinémie de type II ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est établi par des analyses sanguines mesurant les niveaux de lipides."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le profil lipidique et éventuellement des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels niveaux de LDL indiquent ce type d'hyperlipoprotéinémie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux de LDL supérieurs à 160 mg/dL sont souvent indicatifs."
}
},
{
"@type": "Question",
"name": "L'hyperlipoprotéinémie de type II est-elle héréditaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être héréditaire, souvent liée à des mutations génétiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, mais des dépôts de cholestérol peuvent apparaître sur la peau."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de cette condition ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des patients sont asymptomatiques, mais des douleurs thoraciques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on observer des dépôts cutanés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent se former sur la peau en raison de l'accumulation de lipides."
}
},
{
"@type": "Question",
"name": "L'hyperlipoprotéinémie de type II cause-t-elle des douleurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement asymptomatique, mais peut entraîner des douleurs si des complications surviennent."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent apparaître ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des arcus cornéens peuvent être visibles chez certains patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes liés aux maladies cardiovasculaires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'angine de poitrine peuvent survenir en cas de complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperlipoprotéinémie de type II ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier sont des mesures préventives clés."
}
},
{
"@type": "Question",
"name": "Le contrôle du poids est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, maintenir un poids santé aide à réduire le risque d'hyperlipoprotéinémie."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il cette condition ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de maladies cardiovasculaires associées."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils nécessaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans lipidique réguliers aident à détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "L'éducation sur la santé est-elle utile ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sensibiliser à l'importance d'un mode de vie sain est essentiel pour la prévention."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette condition ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire les niveaux de LDL."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie sont-ils recommandés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation saine et l'exercice régulier sont essentiels pour la gestion."
}
},
{
"@type": "Question",
"name": "Des médicaments autres que les statines sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments comme les inhibiteurs de PCSK9 peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi médical ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les niveaux de lipides."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi approprié, les traitements peuvent réduire significativement les risques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'athérosclérose et les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hyperlipoprotéinémie de type II peut-elle causer des AVC ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle augmente le risque d'accidents vasculaires cérébraux en raison de l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de crise cardiaque ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de LDL augmentent le risque de crise cardiaque."
}
},
{
"@type": "Question",
"name": "Comment l'hyperlipoprotéinémie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des maladies rénales en raison de l'athérosclérose des vaisseaux rénaux."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, et une alimentation riche en graisses saturées."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 45 ans chez les hommes et 55 ans chez les femmes."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur cette condition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des comportements malsains et à l'hyperlipoprotéinémie."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hyperlipoprotéinémie augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète de type 2 est un facteur de risque majeur pour l'hyperlipoprotéinémie."
}
}
]
}
]
}
Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Welch Center for Prevention, Epidemiology, and Clinical Research, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Provincial Key Laboratory of Biotechnology, Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an 710069, China.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 increases the rate of...
Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical...
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme rel...
To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy....
This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy w...
We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading ...
PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular p...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical rele...
In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed usi...
The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors includi...
Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at h...
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses. Using R...
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhib...
To identify barriers to prescribing PCSK9 inhibitors in hospitalised patients with ASCVD....
A retrospective 3-month, single-site, observational analysis was conducted in consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. L...
Of 331 patients, 244 (73.7%) underwent PCI and 87 (26.3%) underwent CABG surgery. A lipid profile during or within 8 weeks of admission was measured for 202 (82.8%) patients undergoing PCI and 59 (67....
Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i ther...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating th...
This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-fem...
Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrin...
Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological m...
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce an...
Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved an...
Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patie...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation in...